# Non-invasive fasciculation assessment of

# 2 gastrocnemius failed to show diagnostic or

# 3 prognostic utility in ALS

5 Authors

4

10

- 6 Robbie Muir<sup>1</sup>\*, Brendan O'Shea<sup>1</sup>\*, Raquel Iniesta<sup>2</sup>, Urooba Masood<sup>1</sup>, Cristina Cabassi<sup>1</sup>,
- 7 Domen Planinc<sup>1</sup>, Emma Hodson-Tole<sup>3</sup>, Emmanuel Drakakis<sup>4</sup>, Martyn Boutelle<sup>4</sup>, Christopher
- 8 E Shaw<sup>1,5,6</sup> & James Bashford<sup>1</sup>
- 9 \*First authorship is shared.
- 11 Affiliations
- <sup>1</sup>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience
- 13 Institute, King's College London, London, UK
- <sup>2</sup>Department of Biostatistics and Health Informatics, King's College London, London, UK
- <sup>3</sup>Department of Life Sciences, Musculoskeletal Sciences and Sports Medicine Research
- 16 Centre, Manchester Metropolitan University, Manchester, UK
- <sup>4</sup>Department of Bioengineering, Imperial College London, London, UK
- <sup>5</sup>UK Dementia Research Institute Centre at King's College London, School of Neuroscience,
- 19 King's College London, Strand, London, WC2R 2LS, UK
- <sup>6</sup>Centre for Brain Research, University of Auckland, 85 Park Road, Grafton, Auckland, 1023,
- 21 New Zealand

22

28

303132

- 23 Correspondence: Dr James Bashford, Maurice Wohl Clinical Neuroscience Institute, King's
- 24 College London, 5 Cutcombe Road, London, SE5 9RT, UK.
- 25 E-mail: james.bashford@kcl.ac.uk
- Website: <a href="https://kcl.ac.uk/spige">https://kcl.ac.uk/spige</a>
- 27 Twitter: @SPiQEneurology
- 29 **Word count:** 3523 (excluding references and figure legends)

34 35

36

37

38 39

40

41 42

43 44

45 46

47

48

49

50

51 52

53 54

55

56

57

58 59

60 61

62

63

64 65

66 67

68

697071

**Highlights** Fasciculation parameters from the medial gastrocnemius muscle have poor ability to differentiate ALS patients from controls. Fasciculation parameters from the medial gastrocnemius muscle cannot reliably predict the prognosis Future studies should measure more clinically relevant muscles at an earlier stage in the disease course over a protracted period. **Abstract Objectives** Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder, affecting both upper and lower motor neurons. High-density surface electromyography is a non-invasive measure of muscle fasciculations, a phenomenon prevalent early in the disease. Previous studies highlighted the clinical importance of these measures from the biceps brachii muscle. Our study aimed to investigate the diagnostic and prognostic value of the medial gastrocnemius muscle. **Methods** We performed a retrospective study of 49 ALS and 25 control participants. Means comparisons, logistic regression, receiver operating characteristic analysis, Kaplan-Meier analysis, and a multilevel Cox model were used to determine the predictive utility of fasciculation potential (FP) parameters including FP frequency, median amplitude, and amplitude dispersion. Results FP parameters demonstrated a poor ability to differentiate between ALS and controls, with ROC analysis producing areas under the curve between 0.58 and 0.63. Furthermore, there was no association between FP parameters and ALS prognosis in the Cox model. **Conclusions** FP parameters from the medial gastrocnemius muscle are not useful for the diagnosis or prognosis of ALS patients.

73 74

75

76 77

78 79

80

818283

84 85

86

87

88

89

90

91

92 93

94 95

96

97

98

99

100

101102

103

104

105

106

107

108

109

110

**Significance** Our results highlight the poor clinical utility of fasciculation quantification in the medial gastrocnemius muscle. Future studies should focus on recordings from more clinically relevant muscles earlier in the disease. **Keywords** Amyotrophic lateral sclerosis; medial gastrocnemius muscle; high-density surface electromyography; fasciculation potential; biceps brachii muscle; diagnosis; prognosis. List of abbreviations ALS, amyotrophic lateral sclerosis; UMN, upper motor neuron; LMN, lower motor neuron; HDSEMG, highdensity surface electromyography; MU, motor unit; FP, fasciculation potential; EMG, electromyography; BB, biceps brachii; ROC, receiver operating characteristic; CHAID, chi squared automatic interaction detection; CI, confidence interval; MG, medial gastrocnemius; ENCALS, European Network to Cure ALS; BFS, benign fasciculation syndrome; PN, peripheral neuropathy; MMN, multifocal motor neuropathy; ALSFRS-R, revised amyotrophic lateral sclerosis functional rating scale; SPiQE, surface potential quantification engine, IQR, interquartile range; ANOVA, analysis of variance. 1. Introduction Amyotrophic lateral sclerosis (ALS) is a chronic progressive paralytic disorder, characterised by the degeneration of both upper motor neurons (UMNs) and lower motor neurons (LMNs) (Brown and Al-Chalabi, 2017). The ultimate consequence of the condition is progressive muscle weakness leading to death, usually from respiratory failure, with a median survival time of approximately 19 months from diagnosis and 30 months from symptom onset (Gordon, 2013). However, due to disease heterogeneity and several clinical subtypes, it is difficult to predict individual patient survival early in the disease (Van Es et al., 2017). It is estimated that there are 5000 people living with ALS in the UK at any one time (Opie-Martin et al., 2021), its prevalence higher in men than in women and its incidence increasing with age (Gordon, 2013). However, the onset of ALS is often non-specific and mimics several more common, benign conditions (Van Es et al., 2017). To make a diagnosis, clinicians rely on guidelines such as the Gold Coast criteria (Hannaford et al., 2021), taking a median of 11.5 months after symptom onset (Paganoni et al., 2014) to reach a diagnosis, a third of patients' life expectancy (Van Es et al., 2017). As a result, in recent years there has been much interest garnered towards identifying the pre-symptomatic stage of the disease and stratifying patients with similar life expectancies. The benefit of such developments would be two-fold. Firstly, by grouping patients into similar clinical subtypes, it could allow for the earlier identification of ALS patients. In turn, this would enhance their

112

113

114

115116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131132

133

134

135

136

137

138

139

140

141

142143

144

145

146

147148149150

recruitment into clinical trials when more motor neurons remain viable (De Carvalho et al., 2008), and therapeutic intervention may be more likely to prevent or delay disease progression (Benatar et al., 2019). Secondly, the prognosis of ALS varies greatly and through the development of a reliable prognostic model, patients could take greater control of their lives and make better plans for their future. There are several avenues for research, including genetic markers, fluid biomarkers, and neurophysiological techniques (Van Es et al., 2017). In particular, high-density surface electromyography (HDSEMG) provides a promising option as a non-invasive method of recording fasciculations, capable of revealing LMN involvement in body regions otherwise regarded as unaffected (De Carvalho et al., 2008). Fasciculations are spontaneous, involuntary muscle twitches produced by active motor units (MUs), detected as fasciculation potentials (FPs) on electromyography (EMG) (Drost et al., 2007). They are widespread in ALS and can occur in multiple different muscles (Liu et al., 2021) but can also occur in ALS-mimicking disorders and healthy individuals, making their diagnostic utility uncertain (Noto et al., 2018). FPs are frequently the first abnormality recorded by EMG during neurogenic change in ALS (de Carvalho and Swash, 2013), and their importance in its diagnosis has been increasingly recognised, forming a key component of the Gold Coast criteria (Hannaford et al., 2021). While present in healthy individuals and ALS-mimicking disorders, they are shown to have an increased prevalence and specific morphology in ALS (Bashford et al., 2020c). This may be explained by the underlying pathophysiology of the disease, where denervated muscle fibres are reinnervated by surrounding, healthy MUs through the process of chronic partial reinnervation, allowing strength to be maintained early in the disease course (Bashford et al., 2020c). A previous HDSEMG study by our group showed that FP frequency from biceps brachii (BB) is a valuable predictive marker of ALS, demonstrating an area under a receiver operating characteristic (ROC) analysis curve of 0.89 (95% confidence interval (CI) 0.81-0.98). Chi squared automatic interaction detection (CHAID) decision tree analysis also confirmed FP frequency to be the single best diagnostic measure, showing an 85.9% predictive accuracy (95% CI 75-93.4%) (Tamborska et al., 2020). Prognostically, previous research has shown that FP frequency increases predominately in the early stage of the disease course (Bashford et al., 2020c, Tsugawa et al., 2018), and the rate of change of this process is associated with a higher disease burden (Wannop et al., 2021, Avidan et al., 2021). However, studies have shown that the frequency and amplitude of FPs may fluctuate as the disease progresses (Bashford et al., 2020c), raising the question to its utility as a diagnostic and prognostic tool. Given the evidence provided by our group for the diagnostic and prognostic utility of FP parameters recorded by HDSEMG in the BB muscle (Tamborska et al., 2020, Wannop et al., 2021), the aim of this study was to explore whether these same parameters were equally insightful in the medial gastrocnemius (MG) muscle among 49 ALS patients and 25 control participants.

151 2. Methods 152 153 2.1 Study design 154 155 This study is a retrospective data analysis, using data from three observational studies undertaken at King's 156 College Hospital, London, UK. Using the clinical parameters of the patients with ALS, a prospective dataset 157 containing predicted survival length was obtained using the European Network to Cure ALS (ENCALS) 158 Survival Model (Westeneng et al., 2018). 159 160 2.2 Ethical approval 161 162 Ethical approval was obtained from Research Ethics Services in the North of Scotland (ref: 15/NS/0103), East 163 Midlands (ref: 17/EM/0221), and Yorkshire and the Humber (ref: 19/YH/0164). 164 165 2.3 Participants 166 167 Patients attending the motor nerve clinic at KCH between January 2016 and January 2022 were invited to take 168 part in the studies. These included males and females aged 18-80 who were ambulatory and able to give 169 informed consent. Patients were recruited into two groups: ALS (n=49), and neurological controls (n=8) (Table 170 1). Those recruited into the ALS group were deemed eligible if they were diagnosed with possible, probable, or 171 definite ALS according to the El Escorial criteria within 24 months of symptom onset. Criteria for exclusion 172 included those with atypical or regionally restricted ALS and those with advanced ALS (wheelchair-bound or 173 dependent on non-invasive ventilation). Patients with bulbar onset ALS were required to demonstrate objective 174 involvement in at least one limb. 175 176 Those recruited into the neurological control group were deemed eligible if they were diagnosed with an ALS-177 mimicking disorder by a clinician with an expertise in motor neuron disease. The main criterion for exclusion 178 was diagnostic uncertainty. This group consisted of patients with benign fasciculation syndrome (BFS), 179 peripheral neuropathy (PN), and multifocal motor neuropathy (MMN). Electronic health records of these 180 individuals were inspected at a minimum of two years from recruitment, and none had subsequently developed 181 ALS. 182 183 The healthy control group (n=17) was recruited from Manchester Metropolitan University between May and 184 September 2019 via poster adverts. This group consisted of males and females aged 18-80 who were deemed 185 eligible if they were ambulatory, able to give informed consent, and had no self-reported history of any 186 neurological condition. 187 188 189 190

192 193

194

195

196

197

198 199

200201

202

203

204

205

206

207

208

209

210211

212213

214

215

216

217

218219

220221

222

223

224225

226227

228

229

230

2.4 Clinical assessment All patients' demographic information, including site and date of first symptoms, were recorded where possible. All participants within the ALS and neurological control groups underwent baseline neurological examination, and ALS patients were subsequently classified into the following phenotypes: i) bulbar-onset, ii) cervical-onset, iii) flail arm, iv) lumbar-onset. The disease severity of all participants was determined using the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) at the time of assessment. 2.5 HDSEMG recording Participants underwent either 15- or 30-minute HDSEMG recordings of the BB and MG muscles unilaterally or bilaterally, depending on the original study protocol. The adhesive HDSEMG sensor (comprised of 64 electrodes, arranged in an 8 x 8 grid, electrode diameter 4.5mm, inter-electrode distance 8.5mm; TMS International BV, The Netherlands) was applied centrally over the muscle while the patient was asked to relax in a semi-recumbent position. A reference electrode (3 x 5 cm) was located over the olecranon (when recording BB) and over the dorsum of the foot (when recording MG). Signal amplification was carried out using the Refa-64 Recording System (TMS International, BV, Netherlands), and the raw HDSEMG data were stored as a Polybench file at 2048Hz/channel and processed using the novel surface potential quantification engine (SPiQE) tool (Bashford et al., 2019). 2.6 Fasciculation potential parameters Of all the summary parameters derived from the HDSEMG data by SPiQE, we focused on the following three for the purpose of this study: FP frequency, FP median amplitude, and FP amplitude dispersion. FP frequency is defined as the number of FPs divided by minutes of analysed recording (FP/min). FP median amplitude is defined as the median peak-peak voltage of all FPs detected in each recording (µV). Finally, FP amplitude dispersion is defined as the interquartile range (IQR) of all FP amplitudes detected in each recording ( $\mu$ V). 2.7 Statistical analysis Participant characteristics were summarised using descriptive statistics for all groups. Where bilateral recordings were taken, the values from the side on which the maximal values were recorded were included in the analysis. 2.7.1 Diagnostic All values were transformed to log(10) to satisfy normality for the statistical tests and the normal distribution, and homogeneity of variance of the transformed values were investigated using Shapiro-Wilk normality tests, inspection of Q-Q plots, and Levene's tests. Mean comparisons of the FP parameters between groups was carried out using Welch's one-way analysis of variance (ANOVA) with the Games-Howell post hoc test. To

assess the association of FP parameters with the diagnosis of ALS, we dichotomised the outcome by combining the neurological and healthy control groups (1=ALS, 0=not ALS), and performed univariate binary logistic regression, followed by ROC analysis for the assessment of diagnostic utility. To further explore the diagnostic utility, we carried out a CHAID decision tree classification model with 3-fold internal cross-validation, using each of the FP parameters as independent variables. Unless stated otherwise, values were rounded to the nearest third decimal for p-values and the nearest second decimal for remaining values. The threshold for statistical significance was set to p < 0.05 and all statistical analyses were carried out using IBM SPSS Statistics software (version 28, IBM Corp, Armonk, NY, USA).

2.7.2 Prognostic

Prognostic analysis was performed using R version 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria). There were two datasets used in our analysis.

Our first analysis used a prospective survival prediction from a cohort of patients using the ENCALS Survival Model. This prediction was based on each patient's disease characteristics at their first assessment. Using the same patient cohort in our second analysis, we followed all patients over time and in those patients who died, we recorded the observed survival time for each patient. Those who were still alive at the recording cut-off point, 22<sup>nd</sup> February 2022, were included as censored in our survival analysis.

A Kaplan-Meier analysis was used to identify the most statistically significant parameters, which were then included in a Cox proportional hazards model. A multilevel Cox model was chosen to evaluate the relationship between muscle FP parameters and disease prognosis, while accounting for the presence of bilateral muscle recordings. This was performed for both predicted and observed survival times. Both Cox models were then evaluated using the cox.zph() function, which showed no violations of the proportional hazards assumption.

#### 3. Results

### 3.1 Participant characteristics

Characteristics	ALS	Neurological controls	Healthy controls
n =	49	8	17
Sex			
Female (%)	11 (22)	1 (12.5)	7 (41)
Male (%)	38 (78)	7 (87.5)	10 (59)
Age at onset (years)			
Median (IQR)	59 (51-64)		
Bulbar onset			
Bulbar (%)	12 (24.5)		
Non-bulbar (%)	37 (75.5)		

## Diagnostic delay

(months)				
Median (IQR)	14 (7-21)			
		D: :		
El Escorial diagnosis	10 (05)	Diagnosis	(75)	
Definite (%)	12 (25)	BFS (%)	6 (75)	
Probable (%)	35 (71)	MMN (%)	1 (12.5)	
Possible (%)	2 (4)	PN (%)	1 (12.5)	
ALS phenotype				
Bulbar (%)	12 (24.5)			
Cervical (%)	21 (42.9)			
Flail arm (%)	2 (4)			
Lumbar (%)	14 (28.6)			
C9orf72 repeat				
expansion				
Positive (%)	2 (4)			
Negative (%)	17 (35)			
Not requested (%)	30 (61)			
Age at HDSEMG (years)				
Median (IQR)	61 (53-66)		40 (37-56)	42 (34-62)
Time from symptom onset to HDSEMG (months)				
Median (IQR)	24 (18-36)		20 (8-34)	
ALSFRS-R score				
Median (IQR)	41 (35-44)			
Time from symptom onset to ALSFRS-R (months)				
Median (IQR)	23 (13-38)			
ALSFRS-R progression rate				
Median (IQR)	0.3 (0.16-0.69)			
Predicted FVC (%)				
Median (IQR)	95 (76-100)			
, , ,	, ,			
ENCALS risk group				
Very long (%)	16 (33)			
Long (%)	12 (25)			
Intermediate (%)	11 (22)			
Short (%)	9 (18)			
Very short (%)	1 (2)			
Predicted survival				
(months)				
Median (IQR)	44 (31-63)			
Ob 1				
Observed survival (months)				
Median (IQR)	52 (32-73)*			

Table 1: Participant characteristics. Values rounded to the nearest integer where appropriate. \*Observed survival data was recorded for 21 patients, with 28 surviving patients censored from the analysis. Abbreviations: ALS, amyotrophic lateral sclerosis; IQR, interquartile range; BFS, benign fasciculation syndrome; MMN, multifocal motor neuropathy; PN, peripheral neuropathy; HDSEMG, high-density surface electromyography; ALSFRS-R, amyotrophic lateral sclerosis functional rating scale revised; FVC, forced vital capacity; ENCALS, The European Network to Cure ALS.

### 3.2 Diagnostic

#### 3.2.1 Comparison of fasciculation potential parameters from medial gastrocnemius between groups

Fasciculation parameter n =	<b>ALS</b> 49	Neurological controls 8	Healthy controls 17	Statistical significance
FP frequency (FP/min) Median (IQR)	31 (8.25- 92.35)	13.08 (6.54- 35.41)	14.65 (8.55- 33.8)	Welch's ANOVA $W_{2, 19.21} = 1.71$ $p = 0.207$
$\begin{aligned} &FP \ median \ amplitude \\ &(\mu V) \\ &Median \ (IQR) \end{aligned}$	23.6 (20.2- 41.85)*	26.6 (21-39.83)	28.8 (24.95- 34.95)	Welch's ANOVA $W_{2, 19.08} = 0.28$ $p = 0.757$
FP amplitude dispersion (μV) Median (IQR)	21 (11.08- 31.43) <sup>†</sup>	24.95 (20.5- 31.3)	33.5 (22.3- 56.5)	Welch's ANOVA $W_{2, 23.82} = 2.00$ p = 0.157

Table 2: Comparison of fasciculation parameters from medial gastrocnemius between groups.  $^*FP$  median amplitude data missing from 1 participant (n=48).  $^\dagger FP$  amplitude dispersion data missing from 1 participant (n=48). Abbreviations: ALS, amyotrophic lateral sclerosis; FP, fasciculation potential; min, minute; IQR, interquartile range; ANOVA, analysis of variance.

Welch's ANOVA with Games-Howell *post-hoc* test revealed no statistically significant differences between the groups for each of the FP parameters. The results of these analyses are summarised in *Fig. 1* and *Table 2*.

3.2.2 Association of fasciculation potential parameters with the diagnosis of ALS

In the univariate binary logistic regression, none of the FP parameters were significantly associated with the diagnosis of ALS (FP frequency, p = 0.117; FP median amplitude, p = 0.910; FP amplitude dispersion, p = 0.083).

290291

292

293

294

295

296

297298299

300 301

302 303

304

305

306

307

308

309

310311

312

313

314

315

316

317318

319320

321

322

323

324

325

326

327

328

3.2.3 Assessment of diagnostic utility We further explored the diagnostic utility of these FP parameters by carrying out a ROC analysis (Fig. 2). FP frequency, FP median amplitude and FP amplitude dispersion displayed areas under the curve (AUCs) of 0.61 (95% CI 0.48-0.74, p = 0.134), 0.58 (95% CI 0.44-0.71, p = 0.299), and 0.63 (95% CI 0.50-0.76, p = 0.073)respectively, each indicative of poor diagnostic instruments. Lastly, we carried out a CHAID decision tree classification model of ALS, using the FP parameters from the MG alone as independent variables. Due to their redundancy, none of the MG FP parameters were included as independent variables in the model. 3.3 Prognostic 3.3.1 Association of fasciculation potential parameters with the prognosis of ALS Median values (with IQR) across the cohort for FP frequency, FP median amplitude, and FP amplitude dispersion were 38.5 FP/min (10.3-77.6), 24.9 μV (21.3-45.2), and 24.3 μV (14.8-37.9), respectively. Log-rank analysis of the Kaplan-Meier curves for our predicted survival showed no statistically significant differences for any of the muscle FP parameters, as seen in Fig. 3. However, there was a clear divergence between the dichotomized values of FP median amplitude, therefore this parameter was chosen for Cox proportional hazards analysis. FP median amplitude was associated with a hazard ratio of 1.003 (0.97 - 1.03, p = 0.83) after accounting for bilateral recordings in our dataset. Similarly, as seen in Fig. 4, there were no statistically significant differences in the Kaplan-Meier curves of fasciculations in the observed survival dataset (observed survival data was recorded for 21 patients, with 28 surviving patients censored from the analysis). Similarly, while not significant, there were clear divergences in dichotomized values for FP frequency and FP median amplitude, thus they were implemented in a Cox model. FP frequency and FP median amplitude were associated with hazard ratios of 1.00 (0.99-1.01, p = 0.96) and 1.00 (0.98-1.03, p = 0.97), respectively. 4. Discussion Fasciculations are a hallmark clinical feature of ALS and are reflective of early neuronal dysfunction. Therefore, their measurement and interpretation have the potential to elucidate the processes of neurodegeneration in the early stages of the disease course (Bashford et al., 2019) and expedite diagnosis and prognosis. Despite the evident potential of HDSEMG as a diagnostic or prognostic tool in ALS, it is currently not validated for use in the clinic and remains confined to the research setting. ALS diagnosis and prognosis require an integrative approach, making use of clinical history, physical examination and electrodiagnostic tests (Goutman et al., 2022). Since fasciculation assessment in MG performed poorly as a diagnostic and prognostic tool in isolation, we could not justify planned combinatorial analysis with the BB data. However, this study reinforces a statistical framework for the future inclusion of multiple muscles as part of a clinically relevant body-map

330

331

332 333

334 335

336

337

338

339

340

341

342

343

344

345

346

347

348349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365366367368

assessment. Future work is planned from our group, which will focus on the assessment of muscles known to become weak early in the disease course, such as first dorsal interosseous, abductor pollicis brevis, and tibialis anterior. 4.1 Poor diagnostic utility of gastrocnemius HDSEMG data Our results show that HDSEMG recording in the MG fails to add any additional diagnostic insight above that already provided by recordings in the BB (Tamborska et al., 2020). This finding is corroborated by previous comparisons of gastrocnemius FP parameters between ALS and neurological controls, showing similar spatial distribution, intensity (the number of FP pairs), amplitude, duration, and number of phases (FP repeats within 10-110 ms) between groups (Van Der Heijden et al., 1994, Kleine et al., 2012, Sleutjes et al., 2016). Fermont showed that fasciculations occur frequently in the lower leg muscles of healthy people and may be temporarily increased by physical exercise (Fermont et al., 2010), with the theory being that exercise may induce this increase via metabolic stress. The gastrocnemius has also shown more diurnal variation in FP frequency than the BB (Bashford et al., 2020a), suggesting values recorded in the gastrocnemius may be more sensitive to the exact timing of HDSEMG recording than in BB. Furthermore, fasciculations in ALS patients have been shown to occur more often in proximal than in distal muscles, and markedly more frequently in the upper than in the lower limbs (Krarup, 2011), further promoting the use of BB or other upper limb muscles in the future assessment of the utility of HDSEMG in ALS. The limited diagnostic utility of the MG HDSEMG recordings may also be explained by the differences in disease stage between the participants recruited into this study. It has previously been proposed that FP frequency may increase in the early stages of ALS until muscle weakness occurs, after which it subsequently declines (Tamborska et al., 2020). This initial increase may be attributed to the progression of axonal membrane abnormality in the affected neurons (Mills, 2010), whereas the subsequent fall may be attributed to shrinkage of the MU pool and saturation (or reversal) of the relative hyperexcitability of the surviving MUs (Bashford et al., 2020c). Considering this, the time point at which each patient undergoes HDSEMG recording may bear an influence on their FP parameter values, as they may be at different stages of their disease course and exhibiting varying stages of neuropathophysiology. Furthermore, the fascicle architecture of the two muscles may have an impact on their relative sampling of MUs. In comparison to the parallel architecture of the BB, the fascicles of the gastrocnemius have a pennate architecture with spatially localised MU territories (Vieira et al., 2011). So, the extent to which the position of the electrode grid influences which MUs are within the detection volume may be greater in the gastrocnemius than in the BB (where the majority of MUs would run beneath the grid). Furthermore, variability in the data analyses between studies e.g., differences in methods of determining FP discharge frequency (De Carvalho and Swash, 2016, Noto et al., 2018), may have a significant influence on studies' results and their subsequent interpretation.

370371

372

373

374 375

376

377

378

379

380

381

382

383

384

385

386

387 388

389

390

391

392

393

394

395

396

397 398

399

400

401

402 403

404 405

406

407

408

4.2 Poor prognostic utility of gastrocnemius HDSEMG data Similarly, our study has shown that muscle FP parameters obtained from the MG muscle are not useful at prognosticating patients with ALS. This result was mirrored using both predicted survival values from the ENCALS Survival Model and real-world observed values. While our findings are in contradiction with a previous study which focused on BB (Wannop et al., 2021), there are several plausible explanations. This is the first study aimed solely at the prognostic utility of the MG muscle. When examined histologically, the gastrocnemius muscle is comprised mainly of fast-twitch muscle fibres in comparison to the roughly equal ratio of fast twitch to slow twitch found in the BB muscle (Silva Cornachione et al., 2011, Srinivasan et al., 2007). This nuance is important as ALS is known to preferentially affect fasttwitch muscle fibres (Atkin et al., 2005). Therefore, as muscle FP parameters are known to fall with disease progression (Bashford et al., 2020c), one may speculate that the disease may progress rapidly in the gastrocnemius and may only prove to be a useful measurement much earlier in the disease course. When examining our patient population, HDSEMG recordings were not performed at the time of symptom onset, with the interquartile range 19-34 months after symptom onset. Therefore, it is possible to speculate that the clinical utility of the MG muscle may have been lost long before recordings were taken, and future studies should aim to obtain recordings as soon as a clinical suspicion of ALS arises. Additionally, we chose a different approach for expressing our fasciculation measures than those employed by Wannop et al. (Wannop et al., 2021). Where our study used single-timepoint, 'raw' recordings, Wannop et al. (Wannop et al., 2021) divided these values by months since symptom onset. We decided against implementing this approach in our study. Firstly, as the ENCALS Survival Model uses time variables to produce a predicted survival time, we wanted to avoid spurious correlations, whereby longer prognoses were incorrectly associated with FP parameters (Bashford et al., 2020c). Secondly, there is a weaker relationship between disease progression and change in fasciculation parameters in the MG muscle in comparison to the BB muscle. In particular, weak gastrocnemius muscles show little to no loss of FP frequency as the disease progresses (Bashford et al., 2020c). Through investigating the prognostic utility of the MG muscle, we have shown that HDSEMG recordings have little prognostic utility in the middle-to-late disease course. We have speculated that HDSEMG recordings close to the time of symptom onset may prove to be the most reliable and we hope that the findings from this study can support prospective data collection in other, more reliable muscles. 4.3 Future directions of study This study has shown that the analysis of fasciculations recorded in the MG following symptom onset does not show diagnostic or prognostic utility in ALS. However, HDSEMG may provide a wide range of benefits for ALS patients and their families, as the non-invasive nature of the recording allows for longer recording periods and greater patient comfort (Mateen et al., 2008, Howard and Murray, 1992, Bashford et al., 2019). It is also

410

411

412

413

414

415

416

417

418 419

420

421

422

423

424

425

426

427 428

429

430

431

432

433 434

435 436

437

438

439

440

441442

443 444

445

446

447

448

capable of achieving greater spatial resolution and muscle area coverage than is possible with needle EMG, allowing for more precise anatomical mapping of fasciculations (Drost et al., 2007). Due to this greater coverage, there is also less reliance on the reproduction of needle position in serial recordings, making HDSEMG more suitable for the collection of longitudinal data (Benatar et al., 2016, Bashford et al., 2020b). This is essential for capturing the dynamic changes that occur in ALS due to the inexorable decline of motor neurons (Bashford et al., 2020b). Perhaps the most important benefit of this technique is its ease of application and potential for use outside of the neurophysiology lab. Its use by non-clinicians in the community could provide greater relief to patients and their families as well as benefiting medical research by analysing the disease at a pre-symptomatic stage (Bashford et al., 2020b). Therefore, further research into the application of HDSEMG in the diagnosis and prognosis of neuromuscular disease is required and should focus on the BB or other upper limb muscles at an earlier stage in the disease course. Due to the presence of fasciculations in both ALS patients and controls, HDSEMG data should be considered in the context of other clinical factors, such as the distribution of fasciculations, other neurological symptoms, and a clinical suspicion of ALS (Noto et al., 2018, Mills, 2010, Drost et al., 2007, de Carvalho et al., 2017, De Carvalho et al., 2008). A combinatorial approach may be most appropriate for this, using tools such as electrical impedance myography, ultrasound, and magnetic resonance imaging to monitor clinical, electrophysiological, biochemical, and imaging biomarkers simultaneously. Large numbers of patients across the spectrum of ALS phenotypes should also be monitored in longitudinal studies with post-mortem validation, including prospective multi-centre cohort analyses, to develop reliable and sensitive biomarkers. The greatest diagnostic challenge appears to be in differentiating between ALS and neurological controls. So, a greater range of ALS mimics e.g., spinal muscular atrophy, MMN and spinobulbar muscular atrophy (Kennedy's disease) should be included in neurological control groups. 5. Conclusion The present study has been successful in producing an analytical framework that may be reproduced for the diagnostic and prognostic evaluation of HDSEMG in novel muscle groups. While our results in MG were negative, we believe this study supports the argument for early HDSEMG recordings across a broader range of clinically relevant muscles in patients with ALS, as it is in these early stages of the disease that fasciculations may prove to be the most valuable. 6. Funding JB acknowledges funding from the Medical Research Council and Motor Neurone Disease Association (Lady Edith Wolfson Clinical Research Training Fellowship; MR/P000983/1), Sattaripour Charitable Foundation, UK Dementia Research Institute, and the National Institute for Health and Care Research (Academic Clinical Lectureship program). DP, UM, and CC contributed during their MSc qualifications in Clinical Neuroscience. R.I.'s input represents independent research supported by the NIHR BioResource Centre Maudsley at South

449 London and Maudsley NHS Foundation Trust (SLaM) & Institute of Psychiatry, Psychology and Neuroscience 450 (IoPPN), King's College London. RM acknowledges funding from the Faculty of Life Sciences and Medicine, 451 King's College London. 452 453 7. Competing interests 454 455 The authors declare no relevant competing interests. 456 457 8. Figure legends 458 459 Fig. 1: Comparison of fasciculation potential parameters from medial gastrocnemius between the groups. All values were 460 transformed to log(10). Welch's ANOVA with Games-Howell post-hoc test revealed no statistically significant difference 461 between the means of the groups for each of the fasciculation potential parameters. Abbreviations: FP, fasciculation 462 potential; ALS, amyotrophic lateral sclerosis. 463 464 Fig. 2: Assessment of the diagnostic utility of fasciculation potential parameters recorded in the medial gastrocnemius in 465 ALS. ROC analysis, after dichotomising outcomes by combining the neurological and healthy control groups (I = ALS, 0 =466 not ALS), demonstrated areas under the curve of 0.61, 0.58, and 0.63 for fasciculation frequency, fasciculation amplitude, 467 and fasciculation amplitude dispersion, respectively, each value indicative of a poor diagnostic instrument. 468 469 Fig. 3: A Kaplan-Meier analysis using real-world, observed survival times from a retrospective cohort of patients with ALS. 470 It involved the analysis of three FP parameters: frequency, median amplitude, and amplitude dispersion. Dichotomization 471 into high and low groups occurred at the median value. 472 473 Fig. 4: A Kaplan-Meier analysis using a prospective, predicted patient survival using the ENCALS Survival Model. It 474 involved the analysis of three FP parameters: frequency, median amplitude, and amplitude dispersion. Dichotomization into 475 high and low groups occurred at the median value. 476 477 9. References 478 479 ATKIN, J. D., SCOTT, R. L., WEST, J. M., LOPES, E., QUAH, A. K. J. & CHEEMA, S. S. 2005. Properties of 480 slow- and fast-twitch muscle fibres in a mouse model of amyotrophic lateral sclerosis. Neuromuscular 481 Disorders, 15, 377-388. 482 AVIDAN, R., FAINMESSER, Y., DRORY, V. E., BRIL, V. & ABRAHAM, A. 2021. Fasciculation frequency 483 at the biceps brachii and brachialis muscles is associated with amyotrophic lateral sclerosis disease 484 burden and activity. Muscle & Nerve, 63, 204-208. 485 BASHFORD, J., MASOOD, U., WICKHAM, A., INIESTA, R., DRAKAKIS, E., BOUTELLE, M., MILLS, K. 486 & SHAW, C. 2020a. Fasciculations demonstrate daytime consistency in amyotrophic lateral sclerosis. 487 Muscle & Nerve, 61, 745-750.

BASHFORD, J., MILLS, K. & SHAW, C. 2020b. The evolving role of surface electromyography in amyotrophic lateral sclerosis: A systematic review. *Clin Neurophysiol*, 131, 942-950.

- 490 BASHFORD, J., WICKHAM, A., INIESTA, R., DRAKAKIS, E., BOUTELLE, M., MILLS, K. & SHAW, C.
- 491 2019. SPiQE: An automated analytical tool for detecting and characterising fasciculations in
- 492 amyotrophic lateral sclerosis. Clinical Neurophysiology, 130, 1083-1090.
- 493 BASHFORD, J. A., WICKHAM, A., INIESTA, R., DRAKAKIS, E. M., BOUTELLE, M. G., MILLS, K. R. &
- SHAW, C. E. 2020c. The rise and fall of fasciculations in amyotrophic lateral sclerosis. *Brain*
- 495 *Communications*, 2.
- 496 BENATAR, M., BOYLAN, K., JEROMIN, A., RUTKOVE, S. B., BERRY, J., ATASSI, N. & BRUIJN, L.
- 497 2016. ALS biomarkers for therapy development: State of the field and future directions. *Muscle &*
- 498 *Nerve*, 53, 169-182.
- BENATAR, M., TURNER, M. R. & WUU, J. 2019. Defining pre-symptomatic amyotrophic lateral sclerosis.
- Amyotroph Lateral Scler Frontotemporal Degener, 20, 303-309.
- BROWN, R. H. & AL-CHALABI, A. 2017. Amyotrophic Lateral Sclerosis. New England Journal of Medicine,
- 502 377, 162-172.
- DE CARVALHO, M., DENGLER, R., EISEN, A., ENGLAND, J. D., KAJI, R., KIMURA, J., MILLS, K.,
- MITSUMOTO, H., NODERA, H., SHEFNER, J. & SWASH, M. 2008. Electrodiagnostic criteria for
- diagnosis of ALS. Clinical Neurophysiology, 119, 497-503.
- DE CARVALHO, M., KIERNAN, M. C. & SWASH, M. 2017. Fasciculation in amyotrophic lateral sclerosis:
- origin and pathophysiological relevance. *J Neurol Neurosurg Psychiatry*, 88, 773-779.
- DE CARVALHO, M. & SWASH, M. 2013. Fasciculation potentials and earliest changes in motor unit
- physiology in ALS. J Neurol Neurosurg Psychiatry, 84, 963-8.

510 DE CARVALHO, M. & SWASH, M. 2016. Fasciculation discharge frequency in amyotrophic lateral sclerosis

- and related disorders. *Clinical Neurophysiology*, 127, 2257-2262.
- 512 DROST, G., KLEINE, B. U., STEGEMAN, D. F., VAN ENGELEN, B. G. & ZWARTS, M. J. 2007.
- Fasciculation potentials in high-density surface EMG. *J Clin Neurophysiol*, 24, 301-7.
- 514 FERMONT, J., ARTS, I. M., OVEREEM, S., KLEINE, B. U., SCHELHAAS, H. J. & ZWARTS, M. J. 2010.
- Prevalence and distribution of fasciculations in healthy adults: Effect of age, caffeine consumption and exercise. *Amyotroph Lateral Scler*, 11, 181-6.
- GORDON, P. H. 2013. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology,
- Management and Therapeutic Trials. *Aging Dis*, 4, 295-310.
- 519 GOUTMAN, S. A., HARDIMAN, O., AL-CHALABI, A., CHIÓ, A., SAVELIEFF, M. G., KIERNAN, M. C. &
- FELDMAN, E. L. 2022. Recent advances in the diagnosis and prognosis of amyotrophic lateral
- 521 sclerosis. *Lancet Neurol*, 21, 480-493.
- 522 HANNAFORD, A., PAVEY, N., VAN DEN BOS, M., GEEVASINGA, N., MENON, P., SHEFNER, J. M.,
- 523 KIERNAN, M. C. & VUCIC, S. 2021. Diagnostic Utility of Gold Coast Criteria in Amyotrophic
- Lateral Sclerosis. *Ann Neurol*, 89, 979-986.
- HOWARD, R. S. & MURRAY, N. M. 1992. Surface EMG in the recording of fasciculations. *Muscle Nerve*, 15,
- 526 1240-5.

527 KLEINE, B. U., BOEKESTEIN, W. A., ARTS, I. M. P., ZWARTS, M. J., JURGEN SCHELHAAS, H. & 528 STEGEMAN, D. F. 2012. Fasciculations and their F-response revisited: High-density surface EMG in 529 ALS and benign fasciculations. Clinical Neurophysiology, 123, 399-405. 530 KRARUP, C. 2011. Lower motor neuron involvement examined by quantitative electromyography in 531 amyotrophic lateral sclerosis. Clinical Neurophysiology, 122, 414-422. 532 LIU, J., LI, Y., NIU, J., ZHANG, L., FAN, J., GUAN, Y., CUI, L. & LIU, M. 2021. Fasciculation differences 533 between ALS and non-ALS patients: an ultrasound study. BMC Neurology, 21. 534 MATEEN, F. J., SORENSON, E. J. & DAUBE, J. R. 2008. Strength, physical activity, and fasciculations in 535 patients with ALS. Amyotrophic Lateral Sclerosis, 9, 120-121. 536 MILLS, K. R. 2010. Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign 537 fasciculation syndrome. Brain, 133, 3458-3469. 538 NOTO, Y.-I., SIMON, N. G., SELBY, A., GARG, N., SHIBUYA, K., SHAHRIZAILA, N., HUYNH, W., 539 MATAMALA, J. M., DHARMADASA, T., PARK, S. B., VUCIC, S. & KIERNAN, M. C. 2018. 540 Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral 541 sclerosis. Clinical Neurophysiology, 129, 974-980. 542 OPIE-MARTIN, S., OSSHER, L., BREDIN, A., KULKA, A., PEARCE, N., TALBOT, K. & AL-CHALABI, 543 A. 2021. Motor Neuron Disease Register for England, Wales and Northern Ireland-an analysis of 544 incidence in England. Amyotroph Lateral Scler Frontotemporal Degener, 22, 86-93. 545 PAGANONI, S., MACKLIN, E. A., LEE, A., MURPHY, A., CHANG, J., ZIPF, A., CUDKOWICZ, M. & 546 ATASSI, N. 2014. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). 547 Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15, 453-456. 548 SILVA CORNACHIONE, A., CAÇÃO OLIVEIRA BENEDINI-ELIAS, P., CRISTINA POLIZELLO, J., 549 CÉSAR CARVALHO, L. & CLÁUDIA MATTIELLO-SVERZUT, A. 2011. Characterization of Fiber 550 Types in Different Muscles of the Hindlimb in Female Weanling and Adult Wistar Rats. ACTA 551 HISTOCHEMICA ET CYTOCHEMICA, 44, 43-50. 552 SLEUTJES, B. T. H. M., GLIGORIJEVIĆ, I., MONTFOORT, I., VAN DOORN, P. A., VISSER, G. H. & 553 BLOK, J. H. 2016. Identifying fasciculation potentials in motor neuron disease: A matter of 554 probability. Muscle & Nerve, 53, 227-233. 555 SRINIVASAN, R. C., LUNGREN, M. P., LANGENDERFER, J. E. & HUGHES, R. E. 2007. Fiber type 556 composition and maximum shortening velocity of muscles crossing the human shoulder. Clinical 557 Anatomy, 20, 144-149. 558 TAMBORSKA, A., BASHFORD, J., WICKHAM, A., INIESTA, R., MASOOD, U., CABASSI, C., PLANINC, 559 D., HODSON-TOLE, E., DRAKAKIS, E., BOUTELLE, M., MILLS, K. & SHAW, C. 2020. Non-560 invasive measurement of fasciculation frequency demonstrates diagnostic accuracy in amyotrophic 561 lateral sclerosis. Brain Communications, 2. 562 TSUGAWA, J., DHARMADASA, T., MA, Y., HUYNH, W., VUCIC, S. & KIERNAN, M. C. 2018. 563 Fasciculation intensity and disease progression in amyotrophic lateral sclerosis. Clinical 564 Neurophysiology, 129, 2149-2154.

565 VAN DER HEIJDEN, A., SPAANS, F. & REULEN, J. 1994. Fasciculation potentials in foot and leg muscles of 566 healthy young adults. Electroencephalography and Clinical Neurophysiology/Evoked Potentials 567 Section, 93, 163-168. 568 VAN ES, M. A., HARDIMAN, O., CHIO, A., AL-CHALABI, A., PASTERKAMP, R. J., VELDINK, J. H. & 569 VAN DEN BERG, L. H. 2017. Amyotrophic lateral sclerosis. The Lancet, 390, 2084-2098. 570 VIEIRA, T. M. M., LORAM, I. D., MUCELI, S., MERLETTI, R. & FARINA, D. 2011. Postural activation of 571 the human medial gastrocnemius muscle: are the muscle units spatially localised? The Journal of 572 Physiology, 589, 431-443. 573 WANNOP, K., BASHFORD, J., WICKHAM, A., INIESTA, R., DRAKAKIS, E., BOUTELLE, M., MILLS, K. 574 & SHAW, C. 2021. Fasciculation analysis reveals a novel parameter that correlates with predicted 575 survival in amyotrophic lateral sclerosis. Muscle & Nerve, 63, 392-396. 576 WESTENENG, H.-J., DEBRAY, T. P. A., VISSER, A. E., VAN EIJK, R. P. A., ROONEY, J. P. K., CALVO, 577 A., MARTIN, S., MCDERMOTT, C. J., THOMPSON, A. G., PINTO, S., KOBELEVA, X., 578 ROSENBOHM, A., STUBENDORFF, B., SOMMER, H., MIDDELKOOP, B. M., DEKKER, A. M., 579 VAN VUGT, J. J. F. A., VAN RHEENEN, W., VAJDA, A., HEVERIN, M., KAZOKA, M., 580 HOLLINGER, H., GROMICHO, M., KÖRNER, S., RINGER, T. M., RÖDIGER, A., GUNKEL, A., 581 SHAW, C. E., BREDENOORD, A. L., VAN ES, M. A., CORCIA, P., COURATIER, P., WEBER, M., 582 GROSSKREUTZ, J., LUDOLPH, A. C., PETRI, S., DE CARVALHO, M., VAN DAMME, P., 583 TALBOT, K., TURNER, M. R., SHAW, P. J., AL-CHALABI, A., CHIÒ, A., HARDIMAN, O., 584 MOONS, K. G. M., VELDINK, J. H. & VAN DEN BERG, L. H. 2018. Prognosis for patients with 585 amyotrophic lateral sclerosis: development and validation of a personalised prediction model. The 586 Lancet Neurology, 17, 423-433.







